Compare VRTX & STX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | STX |
|---|---|---|
| Founded | 1989 | 1978 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | EDP Services | Electronic Components |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.6B | 157.1B |
| IPO Year | 2007 | 2002 |
| Metric | VRTX | STX |
|---|---|---|
| Price | $517.10 | $463.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 32 | 26 |
| Target Price | $595.36 | ★ $1,044.83 |
| AVG Volume (30 Days) | 1.3M | ★ 5.0M |
| Earning Date | 11-02-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 0.58% |
| EPS Growth | ★ 836.54 | 105.32 |
| EPS | ★ 10.90 | 7.59 |
| Revenue | $2,488,652,000.00 | ★ $7,384,000,000.00 |
| Revenue This Year | $10.46 | $66.64 |
| Revenue Next Year | $10.53 | $39.78 |
| P/E Ratio | ★ $47.77 | $68.67 |
| Revenue Growth | ★ 46.20 | N/A |
| 52 Week Low | $412.27 | $242.91 |
| 52 Week High | $568.67 | $1,145.00 |
| Indicator | VRTX | STX |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 31.73 |
| Support Level | $493.75 | $449.28 |
| Resistance Level | $536.58 | $939.07 |
| Average True Range (ATR) | 15.90 | 39.09 |
| MACD | -3.73 | 2.81 |
| Stochastic Oscillator | 4.74 | 5.90 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.